_new-therapies-for-transfusion-dependent-mds-patients.jpg "New therapies for transfusion dependent MDS patients from erythroid Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 3 min 28 sec
✓ Published: 02-Dec-2018
✓ Published: 02-Dec-2018
Description:
Dr Alan List speaks to ecancer at ASH 2018 about new therapies for transfusion dependent myelodysplastic syndrome (MDS) patients.nnHe explains that treatments for lower risk MDS patients with anaemia have a short duration of response, therefore there is a need for more effective treatments. One of these is luspatercept, an erythroid maturation agent.nnDr List discusses the results of the Phase III MEDALIST trial, concluding that the use of luspatercept was very durable and that the vast majority
Dr Alan List speaks to ecancer at ASH 2018 about new therapies for transfusion dependent myelodysplastic syndrome (MDS) patients.nnHe explains that treatments for lower risk MDS patients with anaemia have a short duration of response, therefore there is a need for more effective treatments. One of these is luspatercept, an erythroid maturation agent.nnDr List discusses the results of the Phase III MEDALIST trial, concluding that the use of luspatercept was very durable and that the vast majority
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_pure-erythroid-leukaemias.webp "ecancer")
_single-cell-profiling-reveals-key-differences-in-architecture-of-stem-and-progenitor-cells-throughout-life.webp "Dr Roy speaks with ecancer at EHA 23 about observed changes in blood stem cells over at different stages of development, from infancy to adulthood.nnShe describes how, starting from matched liver and bone marrow samples, changes in erythroid, myeloid and lymphoid progenitor cell populations can be charted, and differences between samples indicate a driver of differentiation in the microenvironment.")
⏲ 3 min 78 sec ✓ 16-Jun-2018
_understanding-erythropoiesis.webp "You and MDS")
_erythroid-hypoplasia-3.webp "Katie Boes")
_blood-part-1-true-blood-crash-course-anatomy-amp-physiology-29.webp "CrashCourse")
_hematopoiesis-124-erythropoiesis.webp "Dr Matt u0026 Dr Mike")
_impact-of-mutational-profile-at-diagnosis-for-mds-cml.webp "Dr Montalban-Bravo speaks with ecancer at EHA 2017 about genomic sequencing of over 200 patients at diagnosis, identifying mutational markers which may predict response to hypomethylating agentsnnHe describes that mutations in TET family proteins and p53 were among the most common aberrations, and discusses how treatment pathways can be uncovered through sequencing analysis.nnDr Montalban-Bravo last spoke with ecancer at ASH 2016 about pure erythroid leukaemias.nnFor more on the clinical utility")
_first-day-of-hematology.webp "Dr. Glaucomflecken")
_pure-erythroid-leukaemias.jpg)
_single-cell-profiling-reveals-key-differences-in-architecture-of-stem-and-progenitor-cells-throughout-life.jpg)
_understanding-erythropoiesis.jpg)
_erythroid-hypoplasia-3.jpg)
_blood-part-1-true-blood-crash-course-anatomy-amp-physiology-29.jpg)
_hematopoiesis-124-erythropoiesis.jpg)
_impact-of-mutational-profile-at-diagnosis-for-mds-cml.jpg)
_first-day-of-hematology.jpg)
![[+]](/images/menu.gif){kind=small}